Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLAR: Switch to Long-acting Cabotegravir + Rilpivirine from Biktarvy
NCT04542070Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of cabotegravir, rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Nov 2020; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04542070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542070.